7 results about "In vitro binding" patented technology

The invention relates to the field of liposome manufacturing, and discloses an amphotericin B liposome and a preparation method thereof, and the amphotericin B liposome comprises the following components in parts by mass: 1 part of amphotericin B, 5-10 parts of hydrogenated soybean phospholipid (HSPC), 2-4 parts of cholesterol, 1-3 parts of mPEG2000-DSPE, 0.5-1.5 parts of ceramide, 0.3-0.8 part of glycyrrhetinic acid, 0.2-0.5 part of hydroxyapatite nanoparticles (nHAP) and 8-15 parts of a freeze-drying protective agent. The glycyrrhetinic acid is added, and the specific targeting effect of the glycyrrhetinic acid is utilized, so that the in-vitro binding rate of fungal cells of the lipidosome is improved, the enrichment rate of the medicine at an infected part is further improved, and the core problem of renal toxicity caused by non-targeting distribution of a traditional preparation is effectively solved; the hydroxyapatite nanoparticles adsorb medicine molecules to form a medicine-nHAP compound, and the medicine crystallization rate is greatly reduced by combining the synergistic anti-crystallization effect of the freeze-drying protective agent.

This invention provides an anti-erb-B2 bispecific antibody. It also describes related polynucleotides encoding the provided anti-erb-B2 bispecific antibody or antigen-binding fragment, cells expressing the provided antibody or antigen-binding fragment, and methods for preparing, purifying, and identifying the bispecific antibody. Furthermore, this invention describes the excellent effects of the anti-erb-B2 bispecific antibody, including in vitro binding activity, cancer cell inhibition and killing, and antibody-mediated cytotoxicity. The above-described anti-erb-B2 bispecific antibody can be used to prepare drugs or compositions for treating conditions associated with high erb-B2 expression in individuals.

The application discloses a kind of m6A demethylase ALKBH1 small molecule inhibitor, synthesis method and application, it is related to pharmaceutical technical field, the m6A demethylase ALKBH1 small molecule inhibitor has the chemical structural formula described in formula (I).The m6A demethylase ALKBH1 small molecule inhibitor of the application has biological activity, can be dose-dependent with ALKBH1 protein in vitro Binding, reduces ALKBH1 enzyme activity, has nanomolar level inhibitory activity, while the effect of the small molecule inhibitor to lung cancer cell A549 is verified, for subsequent screening by computer simulation, precise synthesis m6A demethylase ALKBH1 small molecule inhibitor and application in the disease caused by ALKBH1 overexpression provides broad application prospect.

The application belongs to the field of medicine, and discloses a compound or a pharmaceutically acceptable salt, a stereoisomer, a solvate thereof, the structure of which is shown in formula I. In vitro binding efficacy experiments and toxicity experiments of low molecular heparin and the triazine compound of the application show that the triazine compound can produce good combination with low molecular heparin, and can reverse the anticoagulation of heparin, is a safe and low-toxic small molecule compound, and can be used for preparing a medicine for reversing the anticoagulation activity of heparin, treating and / or preventing adverse reactions and diseases caused by excessive heparin anticoagulation. The application discloses the use of the triazine compound or the pharmaceutically acceptable salt, the stereoisomer, the solvate thereof in preparing an anticoagulant reversing agent. The application discloses the use of the triazine compound or the pharmaceutically acceptable salt, the stereoisomer, the solvate thereof in preparing a medicine for treating side effects of excessive anticoagulation caused by using heparin to treat diseases, and preparing a medicine for treating surgical operations in which the anticoagulation activity of heparin needs to be reversed.

The application discloses a new medical use of procyanidin B2 as a carbonic anhydrase IV (CA4) inhibitor. The application first confirms, by surface plasmon resonance (SPR) technology, that procyanidin B2 has direct and specific in-vitro combination with CA4 protein, and the equilibrium dissociation constant KD value is 7.51 μM. The application further confirms, by molecular docking, that the binding energy is-8.4 kcal / mol, which is superior to traditional inhibitors such as acetazolamide. The application further confirms, by molecular dynamics simulation, that the complex has high stability. The application further confirms, by HK-2 cell experiments, that procyanidin B2 can directly down-regulate the background expression of CA4 protein and re-regulate the abnormally high expression of CA4 induced by Ang II. Animal reference examples prove that the acacia extract containing procyanidin B2 can effectively improve the pathological damage of the kidney of SHR rats, reduce collagen deposition, reduce inflammatory factors and restore the folate level by inhibiting CA4. The application provides a new candidate drug molecule for treating renal fibrosis, hypertensive nephropathy and other related diseases by targeting CA4, and has a wide clinical application prospect.

The invention relates to the technical field of biological medicines for specific detection of siderophores in bacterial infection, and discloses a catechol siderophore near-infrared cyanine probe as well as a preparation method and application thereof. According to the research, a siderophore fused near infrared (NIR) fluorescent probe Cl-CA-Cy is developed and is used for detecting pathogenic bacteria. After the probe Cl-CA-Cy is combined with Fe < 3 + > in vitro, a fluorescence signal is quenched, and the fluorescence signal of the probe Cl-CA-Cy is recovered through competitive combination with iron of positive siderophore enterobacter. Besides, introduction of part of chlorine atoms of the chloridecatechol siderophore can prevent host cell catechol-O-methyltransferase from methylating the chloridecatechol siderophore, transport efficiency of the siderophore is improved, and bacterial detection specificity and imaging signal-to-noise ratio of the probe are improved. The research lays a foundation for developing a novel siderophore fluorescent molecular probe for in vivo detection and diagnosis of clinical pathogenic bacteria.

This invention belongs to the field of nanobody technology and provides a method for preparing and applying a single-domain antibody against avian influenza virus H9N2. The application involves using this H9N2 single-domain antibody in the prevention and control of avian influenza virus H9N2. The invention prepares the H9N2 single-domain antibody by immunizing striped bamboo sharks and collecting their tail vein blood. The purity and stability of the H9N2 single-domain antibody were evaluated. The results show that the recombinant single-domain antibody targeting the H9N2 virus HA protein prepared in this invention has high purity and good activity, exhibits good in vitro binding activity with H9N2, and shows good stability at room temperature. The recombinant single-domain antibody 28-H9N2-2SP4H can recognize and bind to the H9N2 virus on the surface of MDCK cell membranes, providing a new direction for the prevention and control of avian influenza as an alternative to traditional antibodies.